Higher radiation dose on immune cells is associated with radiation-induced lymphopenia and worse prognosis in patients with locally advanced esophageal squamous cell carcinoma

被引:3
|
作者
Qiu, Jianjian [1 ]
Lin, Hancui [1 ]
Ke, Dongmei [1 ]
Yu, Yilin [1 ]
Xu, Jiaying [1 ]
Qiu, Hejin [1 ]
Zheng, Qunhao [1 ]
Li, Hui [1 ]
Zheng, Hongying [1 ]
Liu, Lingyun [1 ]
Wang, Zhiping [1 ]
Yao, Qiwei [1 ]
Li, Jiancheng [1 ]
机构
[1] Fujian Med Univ, Fujian Canc Hosp, Clin Oncol Sch, Fuzhou, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2023年 / 14卷
关键词
effective dose to immune cells (EDIC); esophageal carcinoma; radiation-induced lymphopenia (RIL); prognosis; radiotherapy; LYMPHOCYTE NADIR; OPEN-LABEL; CANCER; SURVIVAL; CHEMORADIATION; RADIOTHERAPY; NIVOLUMAB; IMPACT; PEMBROLIZUMAB; MULTICENTER;
D O I
10.3389/fimmu.2023.1066255
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
BackgroundTo explore the effective dose to immune cells (EDIC) for better prognosis while avoiding radiation-induced lymphopenia (RIL) in patients with locally advanced esophageal squamous cell carcinoma (ESCC). Materials and methodsOverall, 381 patients with locally advanced ESCC receiving definitive radiotherapy with or without chemotherapy (dRT +/- CT) between 2014 and 2020 were included in this study. The EDIC model was calculated by radiation fraction number and mean doses to the heart, lung, and integral body. The correlation between EDIC and clinical outcomes was analyzed using Cox proportional hazards regression, and risk factors for RIL were determined by logistic regression analysis. ResultsThe median EDIC was 4.38 Gy. Multivariate analysis revealed that low-EDIC significantly improved the OS of patients when compared with high-EDIC (HR = 1.614, P = 0.003) and PFS (HR = 1.401, P = 0.022). Moreover, high-EDIC was associated with a higher incidence of grade 4 RIL (OR = 2.053, P = 0.007) than low-EDIC. In addition, we identified body mass index (BMI), tumor thickness, and nodal stage as independent prognostic factors of OS and PFS, while BMI (OR = 0.576, P = 0.046) and weight loss (OR = 2.214, P = 0.005) as independent risk factors of grade 4 RIL. In subgroup analyses, the good group had better clinical outcomes than the remaining two groups (P< 0.001). ConclusionThis study demonstrated that EDIC significantly correlates with poor clinical outcomes and severe RIL. Optimizing treatment plans to decrease the radiation doses to immune cells is critical for improving the outcomes.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] The effective radiation dose to immune cells predicts lymphopenia and inferior cancer control in locally advanced NSCLC
    Friedes, Cole
    Iocolano, Michelle
    Lee, Sang Ho
    Duan, Lian
    Li, Bolin
    Doucette, Abigail
    Cohen, Roger B.
    Aggarwal, Charu
    Sun, Lova L.
    Levin, William P.
    Cengel, Keith A.
    Kao, Gary
    Teo, Boon-Keng Kevin
    Langer, Corey J.
    Xiao, Ying
    Bradley, Jeffrey
    Feigenberg, Steven J.
    Yegya-Raman, Nikhil
    RADIOTHERAPY AND ONCOLOGY, 2024, 190
  • [2] The impact of radiation-related lymphocyte recovery on the prognosis of locally advanced esophageal squamous cell carcinoma patients: a retrospective analysis
    Ji, Hongshan
    Zhang, Ping
    Zhen, Chanjun
    Fu, Liyuan
    Lv, Dongjie
    Bai, Wenwen
    Zhang, Rui
    Li, Jing
    Gao, Hang
    Wang, Yajing
    An, Qiuying
    Su, Yuhao
    Si, Hanyu
    Qiao, Xueying
    Zhou, Zhiguo
    RADIATION ONCOLOGY, 2025, 20 (01)
  • [3] Improved survival with higher radiation dose for esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy
    Deng, Yuxia
    Bian, Chao
    Tao, Hua
    Zhang, Haijun
    ONCOTARGET, 2017, 8 (45) : 79662 - 79669
  • [4] The predictors of lymphopenia and its effects on survival in locally advanced esophageal squamous cell carcinoma
    Luo, Danjing
    Zhong, Qiulu
    Yue, Haiying
    Wang, Jue
    Liang, Qianfu
    Liu, Wenqi
    Zhu, Xiaodong
    CANCER BIOLOGY & THERAPY, 2024, 25 (01)
  • [5] Radiation Induced Lymphopenia Is Associated With the Effective Dose to the Circulating Immune Cells in Breast Cancer
    Chen, Fang
    Jin, Jian-Yue
    Hui, Timothy S. K.
    Jing, Haiman
    Zhang, Hong
    Nong, Yaqing
    Han, Ying
    Wang, Weili
    Ma, Lingyu
    Yi, Fan
    Chen, Qingqing
    Zhang, Yongsheng
    Fu, Pingfu
    Yang, Li
    Xu, Zhiyuan
    Kong, Feng-Ming Spring
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [6] High dose radiation with chemotherapy followed by salvage esophagectomy among patients with locally advanced esophageal squamous cell carcinoma
    Lertbutsayanukul, Chawalit
    Tharavej, Chadin
    Klaikeaw, Naruemon
    Prayongrat, Anussara
    Lowanitchai, Chutinan
    Sriuranpong, Virote
    THORACIC CANCER, 2017, 8 (03) : 219 - 228
  • [7] The Role of Lymphocyte Recovery Index in Prognosis Prediction for Locally Advanced Cervical Cancer With Radiation-Induced Lymphopenia
    Li, Yi
    Liu, Ao
    Wang, Xin
    Guo, Longxiang
    Li, Yuanlin
    Liu, Defeng
    Liu, Xiuli
    Li, Zhichao
    Li, Minghuan
    CANCER MEDICINE, 2025, 14 (04):
  • [8] The Impact of Radiation Dose on Preoperative Neoadjuvant Chemoradiotherapy Effects for Patients with Locally Advanced Squamous Cell Esophageal Carcinoma: A Propensity Score-Matched Retrospective Study
    Mu, Yanru
    Wang, Hui
    He, Tao
    Xu, Li
    JOURNAL OF IMMUNOLOGY RESEARCH, 2022, 2022
  • [9] Lymphopenia and Radiation Dose to Circulating Lymphocytes With Neoadjuvant Chemoradiation in Esophageal Squamous Cell Carcinoma
    So, Tsz Him
    Chan, Sik Kwan
    Chan, Wing Lok
    Choi, Horace
    Chiang, Chi Leung
    Lee, Victor
    Lam, Tai Chung
    Wong, Ian
    Law, Simon
    Kwong, Dora
    Kong, Feng Ming
    Jin, Jian Yue
    Lam, Ka On
    ADVANCES IN RADIATION ONCOLOGY, 2020, 5 (05) : 880 - 888
  • [10] The relationship of lymphocyte recovery and prognosis of esophageal cancer patients with severe radiation-induced lymphopenia after chemoradiation therapy
    Deng, Wei
    Xu, Cai
    Liu, Amy
    van Rossum, Peter S. N.
    Deng, Weiye
    Liao, Zhongxing
    Koong, Albert C.
    Mohan, Radhe
    Lin, Steven H.
    RADIOTHERAPY AND ONCOLOGY, 2019, 133 : 9 - 15